...his 17-year tenure at Johnson & Johnson (NYSE:JNJ) last year as VP of immunology scientific innovation.Kura Oncology Inc.... ...was SVP, commercial North America at DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT).
Robin Sawka
Erasca Inc.
City of Hope
Immunovant Inc.
Kura Oncology Inc.
Illumina...
...to the rare disease company’s close of $24.86 on Monday. On Wednesday, precision cancer company Kura Oncology Inc.... ...led by Schlaepfer Family Foundation. Targets AXL (UFO) - AXL receptor tyrosine kinase
BioCentury Staff
Kineta Inc.
BerGenBio A/S
Limbix
Kura Oncology Inc.
Insmed...
...head of genetic diseases at the Genzyme unit of Sanofi (Euronext:SAN; NYSE:SNY). Precision oncology company Kura Oncology Inc.... ...Laboratories L.P.
BioCentury Staff
Guardant Health Inc.
Krystal Biotech Inc.
Roivant Sciences GmbH
Ergomed plc
Galapagos N.V.
Acceleron Pharma Inc.
Eli Lilly and Co.
Kura Oncology Inc....
...Healthcare Partners launched Phathom in May (see “Divergent Aftermarket Results for Phathom, Cabaletta IPOs” ). Kura Oncology Inc.... ...operations at Array Biopharma, which Pfizer Inc. (NYSE:PFE) acquired in July.
BioCentury Staff
Aveo Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc.
Kura Oncology Inc.
Akcea...
...Aridis fell $0.78 to $10.90 on Tuesday. Kura's bladder cancer therapy meets PFS endpoint Kura Oncology Inc.... ...kinase
Sandi Wong and Hongjiang Li, Staff Writers
Aerucin (AR-105)
CTP-543
PB-718
selatogrel (ACT-246475)
tipifarnib (zarnestra, R115777)
Aridis Pharmaceuticals Inc.
Concert Pharmaceuticals Inc.
Idorsia Ltd.
Kura Oncology Inc.
PegBio...
...his 17-year tenure at Johnson & Johnson (NYSE:JNJ) last year as VP of immunology scientific innovation.Kura Oncology Inc.... ...was SVP, commercial North America at DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT).
Robin Sawka
Erasca Inc.
City of Hope
Immunovant Inc.
Kura Oncology Inc.
Illumina...
...to the rare disease company’s close of $24.86 on Monday. On Wednesday, precision cancer company Kura Oncology Inc.... ...led by Schlaepfer Family Foundation. Targets AXL (UFO) - AXL receptor tyrosine kinase
BioCentury Staff
Kineta Inc.
BerGenBio A/S
Limbix
Kura Oncology Inc.
Insmed...
...head of genetic diseases at the Genzyme unit of Sanofi (Euronext:SAN; NYSE:SNY). Precision oncology company Kura Oncology Inc.... ...Laboratories L.P.
BioCentury Staff
Guardant Health Inc.
Krystal Biotech Inc.
Roivant Sciences GmbH
Ergomed plc
Galapagos N.V.
Acceleron Pharma Inc.
Eli Lilly and Co.
Kura Oncology Inc....
...Healthcare Partners launched Phathom in May (see “Divergent Aftermarket Results for Phathom, Cabaletta IPOs” ). Kura Oncology Inc.... ...operations at Array Biopharma, which Pfizer Inc. (NYSE:PFE) acquired in July.
BioCentury Staff
Aveo Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc.
Kura Oncology Inc.
Akcea...
...Aridis fell $0.78 to $10.90 on Tuesday. Kura's bladder cancer therapy meets PFS endpoint Kura Oncology Inc.... ...kinase
Sandi Wong and Hongjiang Li, Staff Writers
Aerucin (AR-105)
CTP-543
PB-718
selatogrel (ACT-246475)
tipifarnib (zarnestra, R115777)
Aridis Pharmaceuticals Inc.
Concert Pharmaceuticals Inc.
Idorsia Ltd.
Kura Oncology Inc.
PegBio...
